Amgen Historical Income Statement

AMGN Stock

USD 280.07 0.06 0.02%

Historical analysis of Amgen income statement accounts such as Interest Expense of 3 B, Selling General Administrative of 5.8 B or Total Revenue of 29.6 B can show how well Amgen Inc performed in making a profits. Evaluating Amgen income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Amgen's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Amgen Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Amgen Inc is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

About Amgen Income Statement Analysis

Amgen Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Amgen shareholders. The income statement also shows Amgen investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Amgen Income Statement Chart

At this time, Amgen's Cost Of Revenue is very stable compared to the past year. As of the 29th of November 2024, Total Operating Expenses is likely to grow to about 12.4 B, while Operating Income is likely to drop about 4.1 B.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Non Operating Income Net Other Selling And Marketing Expenses

Total Revenue

Total revenue comprises all receipts Amgen Inc generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Amgen Inc minus its cost of goods sold. It is profit before Amgen operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Amgen Inc. It is also known as Amgen overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Amgen's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Amgen Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

	2021	2022	2023	2024 (projected)
Interest Expense	1.2B	1.4B	2.9B	3.0B
Depreciation And Amortization	3.4B	3.3B	4.1B	4.3B

Interest Expense Depreciation And Amortization

Amgen income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Selling And Marketing Expenses	Net Interest Income	Reconciled Depreciation	Extraordinary Items	Non Recurring
Depreciation And Amortization		0.78	0.52	0.8	0.68	0.83	0.17	0.43	0.5	0.93	0.68	0.35	0.37	0.53	0.06	0.53	0.43	-0.65	-0.03	-0.61	0.67	-0.77	0.82	0.57	-0.58
Interest Expense	0.78		0.66	0.79	0.68	0.86	0.28	0.33	0.23	0.9	0.76	0.31	0.16	0.54	0.1	0.43	0.39	-0.63	0.04	-0.39	0.47	-0.85	0.59	0.83	-0.84
Selling General Administrative	0.52	0.66		0.87	0.9	0.85	0.64	0.62	0.56	0.66	0.95	0.64	-0.13	0.69	0.18	0.79	0.27	-0.12	0.09	-0.08	0.27	-0.31	0.23	0.29	-0.31
Total Revenue	0.8	0.79	0.87		0.98	0.96	0.59	0.76	0.74	0.89	0.94	0.7	0.19	0.77	0.21	0.81	0.46	-0.35	0.07	-0.26	0.66	-0.53	0.58	0.4	-0.41
Gross Profit	0.68	0.68	0.9	0.98		0.9	0.7	0.83	0.8	0.79	0.93	0.79	0.11	0.79	0.27	0.85	0.43	-0.19	0.12	-0.1	0.6	-0.36	0.44	0.25	-0.27
Other Operating Expenses	0.83	0.86	0.85	0.96	0.9		0.39	0.59	0.56	0.95	0.96	0.5	0.2	0.7	0.07	0.77	0.4	-0.52	-0.04	-0.45	0.59	-0.69	0.66	0.55	-0.56
Operating Income	0.17	0.28	0.64	0.59	0.7	0.39		0.79	0.69	0.24	0.49	0.94	-0.24	0.58	0.5	0.63	0.35	0.39	0.37	0.53	0.21	0.17	-0.15	-0.01	0.17
Ebit	0.43	0.33	0.62	0.76	0.83	0.59	0.79		0.96	0.49	0.63	0.93	0.11	0.66	0.38	0.78	0.42	0.09	0.2	0.13	0.67	-0.04	0.36	-0.02	0.17
Ebitda	0.5	0.23	0.56	0.74	0.8	0.56	0.69	0.96		0.48	0.59	0.87	0.19	0.63	0.34	0.77	0.4	0.08	0.16	0.04	0.7	0.0	0.4	-0.16	0.24
Cost Of Revenue	0.93	0.9	0.66	0.89	0.79	0.95	0.24	0.49	0.48		0.83	0.38	0.34	0.62	0.04	0.62	0.44	-0.67	-0.06	-0.57	0.68	-0.83	0.81	0.66	-0.67
Total Operating Expenses	0.68	0.76	0.95	0.94	0.93	0.96	0.49	0.63	0.59	0.83		0.56	0.07	0.72	0.09	0.83	0.33	-0.35	-0.02	-0.31	0.46	-0.51	0.49	0.41	-0.43
Income Before Tax	0.35	0.31	0.64	0.7	0.79	0.5	0.94	0.93	0.87	0.38	0.56		-0.08	0.64	0.48	0.73	0.42	0.24	0.32	0.34	0.46	0.08	0.11	-0.02	0.2
Total Other Income Expense Net	0.37	0.16	-0.13	0.19	0.11	0.2	-0.24	0.11	0.19	0.34	0.07	-0.08		-0.01	-0.05	0.12	0.05	-0.64	-0.09	-0.43	0.38	-0.41	0.52	0.11	-0.11
Net Income	0.53	0.54	0.69	0.77	0.79	0.7	0.58	0.66	0.63	0.62	0.72	0.64	-0.01		-0.25	0.68	0.86	-0.18	-0.4	-0.23	0.5	-0.32	0.36	0.2	-0.21
Income Tax Expense	0.06	0.1	0.18	0.21	0.27	0.07	0.5	0.38	0.34	0.04	0.09	0.48	-0.05	-0.25		0.08	-0.45	0.33	0.98	0.61	0.15	0.2	-0.14	-0.05	0.07
Research Development	0.53	0.43	0.79	0.81	0.85	0.77	0.63	0.78	0.77	0.62	0.83	0.73	0.12	0.68	0.08		0.36	-0.1	-0.06	-0.17	0.4	-0.2	0.4	0.15	0.06
Net Income From Continuing Ops	0.43	0.39	0.27	0.46	0.43	0.4	0.35	0.42	0.4	0.44	0.33	0.42	0.05	0.86	-0.45	0.36		-0.25	-0.58	-0.29	0.44	-0.35	0.36	0.26	-0.18
Non Operating Income Net Other	-0.65	-0.63	-0.12	-0.35	-0.19	-0.52	0.39	0.09	0.08	-0.67	-0.35	0.24	-0.64	-0.18	0.33	-0.1	-0.25		0.34	0.81	-0.37	0.9	-0.76	-0.69	0.67
Tax Provision	-0.03	0.04	0.09	0.07	0.12	-0.04	0.37	0.2	0.16	-0.06	-0.02	0.32	-0.09	-0.4	0.98	-0.06	-0.58	0.34		0.63	0.03	0.23	-0.23	-0.06	0.04
Interest Income	-0.61	-0.39	-0.08	-0.26	-0.1	-0.45	0.53	0.13	0.04	-0.57	-0.31	0.34	-0.43	-0.23	0.61	-0.17	-0.29	0.81	0.63		-0.31	0.74	-0.78	-0.46	0.46
Selling And Marketing Expenses	0.67	0.47	0.27	0.66	0.6	0.59	0.21	0.67	0.7	0.68	0.46	0.46	0.38	0.5	0.15	0.4	0.44	-0.37	0.03	-0.31		-0.44	0.78	0.18	-0.24
Net Interest Income	-0.77	-0.85	-0.31	-0.53	-0.36	-0.69	0.17	-0.04	0.0	-0.83	-0.51	0.08	-0.41	-0.32	0.2	-0.2	-0.35	0.9	0.23	0.74	-0.44		-0.78	-0.88	0.85
Reconciled Depreciation	0.82	0.59	0.23	0.58	0.44	0.66	-0.15	0.36	0.4	0.81	0.49	0.11	0.52	0.36	-0.14	0.4	0.36	-0.76	-0.23	-0.78	0.78	-0.78		0.53	-0.45
Extraordinary Items	0.57	0.83	0.29	0.4	0.25	0.55	-0.01	-0.02	-0.16	0.66	0.41	-0.02	0.11	0.2	-0.05	0.15	0.26	-0.69	-0.06	-0.46	0.18	-0.88	0.53		-0.8
Non Recurring	-0.58	-0.84	-0.31	-0.41	-0.27	-0.56	0.17	0.17	0.24	-0.67	-0.43	0.2	-0.11	-0.21	0.07	0.06	-0.18	0.67	0.04	0.46	-0.24	0.85	-0.45	-0.8

Click cells to compare fundamentals

Amgen Account Relationship Matchups

Amgen income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	753M	3.6B	3.4B	3.3B	4.1B	4.3B
Interest Expense	1.3B	1.3B	1.2B	1.4B	2.9B	3.0B
Selling General Administrative	4.4B	4.8B	4.5B	4.6B	5.5B	5.8B
Total Revenue	23.4B	25.4B	26.0B	26.3B	28.2B	29.6B
Gross Profit	19.0B	19.3B	19.5B	19.9B	19.7B	20.7B
Other Operating Expenses	13.7B	16.3B	16.8B	16.8B	20.3B	21.3B
Operating Income	9.7B	5.8B	6.0B	5.3B	7.9B	4.1B
Ebit	9.7B	9.3B	9.1B	8.8B	7.9B	4.6B
Ebitda	10.4B	12.9B	12.5B	12.1B	7.9B	5.4B
Cost Of Revenue	4.4B	6.2B	6.5B	6.4B	8.5B	8.9B
Total Operating Expenses	9.3B	10.1B	10.4B	10.4B	11.8B	12.4B
Income Before Tax	9.1B	8.1B	6.7B	7.3B	7.9B	4.0B
Total Other Income Expense Net	(536M)	(1.0B)	696M	2.0B	(42M)	(44.1M)
Net Income	7.8B	7.3B	5.9B	6.6B	6.7B	7.1B
Income Tax Expense	1.3B	869M	808M	794M	1.1B	830.4M
Research Development	4.1B	4.2B	4.8B	4.4B	4.8B	2.9B
Net Income Applicable To Common Shares	7.8B	7.3B	5.9B	6.6B	7.5B	5.0B
Net Income From Continuing Ops	7.8B	7.3B	5.9B	6.6B	7.6B	6.4B
Non Operating Income Net Other	753M	256M	259M	(814M)	(732.6M)	(696.0M)
Tax Provision	1.3B	869M	808M	794M	1.2B	1.4B
Interest Income	928M	674M	753M	256M	230.4M	218.9M
Selling And Marketing Expenses	789M	962M	843M	841M	647M	759.1M
Net Interest Income	(536M)	(1.0B)	(1.2B)	(1.4B)	(2.5B)	(2.3B)
Reconciled Depreciation	2.2B	3.6B	3.4B	3.4B	3.6B	3.2B

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving against Amgen Stock

0.81	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.72	ESPR	Esperion Therapeutics	Pair Corr
0.69	VTRS	Viatris	Pair Corr
0.53	GILD	Gilead Sciences	Pair Corr
0.48	BFRIW	Biofrontera Warrants	Pair Corr

The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.

The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:

How To Invest In Amgen

Details

Is Amgen Stock a good investment?

Details

What is Amgen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.621

Dividend Share

8.88

Earnings Share

7.84

Revenue Per Share

60.641

Quarterly Revenue Growth

0.232

The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amgen Historical Income Statement

About Amgen Income Statement Analysis

Amgen Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Amgen income statement Correlations

Amgen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amgen income statement Accounts

Pair Trading with Amgen

Moving against Amgen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 0.98	Total Revenue
Tax Provision	+ 0.98	Income Tax Expense
Other Operating Expenses	+ 0.96	Total Revenue
Total Operating Expenses	+ 0.96	Other Operating Expenses
Ebitda	+ 0.96	Ebit
Total Operating Expenses	+ 0.95	Selling General Administrative

Extraordinary Items	- 0.88	Net Interest Income
Net Interest Income	- 0.85	Interest Expense
Non Recurring	- 0.84	Interest Expense
Net Interest Income	- 0.83	Cost Of Revenue
Non Recurring	- 0.8	Extraordinary Items
Reconciled Depreciation	- 0.78	Net Interest Income